Alpha 2.0
Login Register
» Articles » PMID: 29458966

Have Clinical Trials Properly Assessed C-Met Inhibitors?

Overview
Journal Trends Cancer
Publisher Cell Press
Specialty Oncology
Date 2018 Feb 21
PMID 29458966
Citations 29
Authors
Veronica S Hughes
Dietmar W Siemann
Affiliations
Soon will be listed here.
Abstract

The c-Met/HGF pathway is implicated in cancer progression and dissemination. Many inhibitors have been developed to target this pathway. Unfortunately, most trials have failed to demonstrate efficacy. However, clinical trials have not adequately tested the concept of c-Met pathway inhibition due to the lack of appropriate patient selection criteria.

Citing Articles

E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network.

Poliakova Turan M, Riedo R, Medo M, Pozzato C, Friese-Hamim M, Koch J Cancer Res Commun. 2024; 4(7):1863-1880.

PMID: 38957115 PMC: 11288008. DOI: 10.1158/2767-9764.CRC-23-0370.

Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling.

Albadari N, Xie Y, Li W Front Pharmacol. 2024; 14:1340401.

PMID: 38269272 PMC: 10806212. DOI: 10.3389/fphar.2023.1340401.

MET exon 14 skipping mutation drives cancer progression and recurrence via activation of SMAD2 signalling.

Liang Q, Hu Y, Yuan Q, Yu M, Wang H, Zhao B Br J Cancer. 2023; 130(3):380-393.

PMID: 38110666 PMC: 10844616. DOI: 10.1038/s41416-023-02495-5.

Phase 1 Study of the Selective c-MET Inhibitor, HS-10241, in Patients With Advanced Solid Tumors.

Dong X, Li X, Chen J, Ma S, Mu D, Hu J JTO Clin Res Rep. 2023; 4(2):100449.

PMID: 36846572 PMC: 9943892. DOI: 10.1016/j.jtocrr.2022.100449.

Crizotinib-based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation.

Chen J, Jin J, Gu W, Zhao Z, Yuan H, Zhou Y Cancer Sci. 2023; 114(5):1958-1971.

PMID: 36692137 PMC: 10154821. DOI: 10.1111/cas.15733.

References
1.
Srivastava A, Hollingshead M, Weiner J, Navas T, Evrard Y, Khin S . Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays. Clin Cancer Res. 2016; 22(14):3683-94. PMC: 7802886. DOI: 10.1158/1078-0432.CCR-15-2323. View
2.
Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J . Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003; 21(12):2237-46. DOI: 10.1200/JCO.2003.10.038. View
3.
Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G . Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012; 12(2):89-103. DOI: 10.1038/nrc3205. View
4.
Janne P, Gurubhagavatula S, Yeap B, Lucca J, Ostler P, Skarin A . Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer. 2004; 44(2):221-30. DOI: 10.1016/j.lungcan.2003.12.014. View
5.
Xie Q, Bradley R, Kang L, Koeman J, Ascierto M, Worschech A . Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A. 2011; 109(2):570-5. PMC: 3258605. DOI: 10.1073/pnas.1119059109. View